09/27/23 8:00 AMNasdaq : FEMY conferenceslow floatFemasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to ParticipateThe first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies - FemBloc is being developed as a first-of-its-kind, non-surgical permanent birth control with a clear U.S. regulatory pathway - ATLANTA, Sept. 27, 2023 (GLOBERHEA-AIneutral
09/25/23 5:25 PMNasdaq : FEMY clinical triallow floatFemasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ® , an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed toRHEA-AIpositive
09/20/23 8:30 AMNasdaq : FEMY clinical triallow floatFemasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth ControlFemasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including two lead revolutionary late-clinical stage product candidates andRHEA-AIneutral
09/06/23 8:30 AMNasdaq : FEMY conferenceslow floatFemasys to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceFemasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovativeRHEA-AIneutral
08/31/23 8:30 AMNasdaq : FEMY low floatFemasys Inc. Obtains Medical Device Establishment License from Health CanadaFemasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovativeRHEA-AIneutral
08/10/23 8:00 AMNasdaq : FEMY earningslow floatFemasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc ® - Three product approvals achieved in Canada for FemaSeed ® , FemCerv ® and FemCath ® products during the second quarter - Raised $3.9 million in a registered direct offering ATLANTA, Aug. 10, 2023RHEA-AIneutral
08/03/23 8:45 AMNasdaq : FEMY low floatFemasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBlocFemasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovativeRHEA-AIneutral
07/27/23 8:45 AMNasdaq : FEMY low floatFemasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth ControlFemasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite ofRHEA-AIneutral
06/26/23 8:00 AMNasdaq : FEMY clinical trialfda approvallow floatFemasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for WomenFemasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologiesRHEA-AIneutral
06/15/23 8:00 AMNasdaq : FEMY managementlow floatFemasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life SciencesFemasys Inc. (NASDAQ: FEMY), a biomedicalRHEA-AIneutral